# OnCo record sugemalimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/sugemalimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "sugemalimab" ;
  schema:name "Sugemalimab"@en ;
  schema:description "Sugemalimab is CStone's PD-L1 antibody, approved in China for first-line lung cancer with chemotherapy and after chemoradiotherapy in stage III disease, and the first China-developed PD-L1 antibody to win European approval."@en ;
  schema:url <https://onco.cc/drugs/sugemalimab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Sugemalimab> ;
  schema:citation <https://www.cstonepharma.com/en/>, <https://doi.org/10.1016/S1470-2045(21)00650-1>, <https://www.ema.europa.eu/en/medicines/human/EPAR/cejemly> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Monoclonal antibody (anti-PD-L1, fully human IgG4)" ;
  schema:alternateName "Cejemly" ;
  onco:approval "China 2021: First-line metastatic squamous and non-squamous NSCLC with platinum chemotherapy (GEMSTONE-302)", "China 2022: Unresectable stage III NSCLC without progression after chemoradiotherapy (GEMSTONE-301)", "EU 2024: First-line metastatic NSCLC with platinum chemotherapy, no sensitising EGFR, ALK, ROS1 or RET alterations" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/stage-iii-unresectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:companies <https://onco.cc/companies/cstone/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:trials <https://onco.cc/trials/gemstone-302/>, <https://onco.cc/trials/nct06617416/>, <https://onco.cc/trials/gemstone-301/> .